Amgen and Sanofi Drugs Can Reach U.S. Without Long StudiesMichelle Fay Cortez and Drew Armstrong
U.S. regulators won’t require Amgen Inc., Sanofi, Pfizer Inc. and other companies developing the next class of cardiovascular medicines to prove the therapies prevent heart attacks and death before they’re approved.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.